ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Cambrex has completed a $38 million expansion at its manufacturing plant for small-molecule active pharmaceutical ingredients in High Point, North Carolina. The project doubles capacity at the site by adding analytical and chemical development laboratories, two clinical manufacturing suites, and three small-scale commercial manufacturing work centers with 2,000 L reactors. The enlarged operation is intended to coordinate with R&D and continuous-flow process development assets that Cambrex acquired last year with its purchase of Snapdragon Chemistry.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X